Sterling Capital Management LLC Has $214,000 Stake in Envista Holdings Co. (NYSE:NVST)

Sterling Capital Management LLC increased its stake in Envista Holdings Co. (NYSE:NVST) by 53.9% in the 4th quarter, according to the company in its most recent filing with the SEC. The fund owned 11,105 shares of the company’s stock after purchasing an additional 3,888 shares during the quarter. Sterling Capital Management LLC’s holdings in Envista were worth $214,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors also recently added to or reduced their stakes in NVST. Venturi Wealth Management LLC lifted its stake in shares of Envista by 528.4% in the fourth quarter. Venturi Wealth Management LLC now owns 1,948 shares of the company’s stock worth $38,000 after buying an additional 1,638 shares during the last quarter. GAMMA Investing LLC lifted its position in Envista by 30.5% during the 4th quarter. GAMMA Investing LLC now owns 2,304 shares of the company’s stock worth $44,000 after acquiring an additional 538 shares during the last quarter. Thurston Springer Miller Herd & Titak Inc. bought a new stake in Envista during the fourth quarter valued at about $53,000. Mitsubishi UFJ Trust & Banking Corp acquired a new stake in shares of Envista in the fourth quarter valued at about $86,000. Finally, KBC Group NV increased its stake in shares of Envista by 63.9% in the fourth quarter. KBC Group NV now owns 7,903 shares of the company’s stock worth $152,000 after purchasing an additional 3,082 shares during the period.

Envista Stock Up 1.1 %

Shares of NYSE NVST opened at $15.19 on Monday. The business has a fifty day moving average of $17.82 and a two-hundred day moving average of $19.21. The company has a debt-to-equity ratio of 0.44, a quick ratio of 1.76 and a current ratio of 2.04. Envista Holdings Co. has a 52-week low of $14.22 and a 52-week high of $23.00. The stock has a market cap of $2.62 billion, a PE ratio of -2.34, a PEG ratio of 1.27 and a beta of 1.12.

Envista (NYSE:NVST) last announced its quarterly earnings results on Wednesday, February 5th. The company reported $0.24 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.23 by $0.01. Envista had a negative net margin of 44.56% and a positive return on equity of 3.86%. As a group, equities research analysts expect that Envista Holdings Co. will post 1 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of research firms have issued reports on NVST. JPMorgan Chase & Co. lowered their target price on Envista from $20.00 to $19.00 and set a “neutral” rating on the stock in a report on Thursday, March 6th. Wells Fargo & Company set a $19.00 price objective on shares of Envista in a research note on Saturday, March 8th. Morgan Stanley set a $16.00 price target on shares of Envista in a report on Tuesday, April 15th. Jefferies Financial Group boosted their price objective on shares of Envista from $20.00 to $22.00 and gave the stock a “hold” rating in a report on Thursday, January 23rd. Finally, Piper Sandler increased their target price on shares of Envista from $17.00 to $18.00 and gave the company a “neutral” rating in a research note on Monday, February 3rd. Two investment analysts have rated the stock with a sell rating, ten have given a hold rating and three have issued a buy rating to the company’s stock. According to data from MarketBeat, the stock presently has an average rating of “Hold” and a consensus price target of $19.96.

About Envista

Envista Holdings Corporation, together with its subsidiaries, develops, manufactures, markets, and sells dental products in the United States, China, and internationally. The company operates in two segments, Specialty Products & Technologies, and Equipment & Consumables. The Specialty Products & Technologies segment offers dental implant systems, guided surgery systems, biomaterials, and prefabricated and custom-built prosthetics to oral surgeons, prosthodontists and periodontists, and general dentist; and brackets and wires, tubes and bands, archwires, clear aligners, digital orthodontic treatments, retainers, and other orthodontic laboratory products.